Advances in diagnosis and management of oligodendroglioma

Expert Review of Anticancer Therapy

Volumn 2, Issue 5, 2002, Pages 520-528

  Hussein, Mohamed R ^a   Baidas, Said ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

CCNU; Chromosomal alteration; Gliomas; Loss of heterozygosity; Oligodendroglioma; PCV; PET; radiotherapy; Remozolomide; Scan

Indexed keywords

CARBOPLATIN; CARMUSTINE; CISPLATIN; COLONY STIMULATING FACTOR; DIAZIQUONE DERIVATIVE; ETOPOSIDE; KI 67 ANTIGEN; LOMUSTINE; MELPHALAN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NITROSOUREA; PROCARBAZINE; TEMOZOLOMIDE; THALIDOMIDE; THIOTEPA; VINCRISTINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; PCV REGIMEN; VINDESINE;

BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CLINICAL FEATURE; COMPARATIVE GENOMIC HYBRIDIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FATIGUE; FEMALE; GENE MUTATION; HERPES ZOSTER; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; LUNG TOXICITY; MALE; NEUTROPENIA; OLIGODENDROGLIOMA; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RASH; REVIEW; SURGICAL TECHNIQUE; THROMBOCYTOPENIA; CYTOGENETICS; GENETICS; PATHOLOGY; RADIOTHERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOGENETICS; HUMANS; OLIGODENDROGLIOMA; PROGNOSIS; RADIOTHERAPY; VINDESINE;

EID: 0036796193     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.2.5.520     Document Type: Review

References (94)

1. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer 83(6), 870-873 (1999).
2. Greenlee RT, Murray T. Cancer statistics, 2001. CA Cancer J. Clin. 51(1), 15-36 (2001).
3. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79(7), 1381-1393 (1997).
4. Daumas-Duport C, Varlet P, Tucker ML, Beuvon F, Cervera P, Chodkiewicz JP. Oligodendrogliomas. Part I: patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J. Neurooncol. 34(1), 37-59 (1997).
5. Daneyemez M, Baysefer A, Can C, Timurkaynak E. Multiple oligodendroglioma: case report. Minimum Invasive Neurosurg. 43(1), 51-52 (2000).
6. Chen R, MacDonald DR, Ramsay DA. Primary diffuse leptomeningeal oligodendroglioma. J. Neurosurg. 83, 724-728 (1995).
7. Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54(7), 1442-1448 (2000).
8. Perry JR, Louis DN, Cairncross JG. Current treatment of oligodendrogliomas. Arch. Neurol. 56(4), 434-436 (1999).
9. Smith MT, Ludwig CL, Godfrey AD, Armbrustmacher VW. Grading of oligodendrogliomas. Cancer 52, 2107-2114 (1983).
10. Bruner JM. Oligodendrgliomas: diagnosis and prognosis. Semin. Diag. Pathol. 4, 251-261 (1987).
11. Ludwig CL, Smith MT, Godfrey AD, Armbrustmacher VW. A clinicopathological study of 323 patients with oligodendrogliomas. Ann. Neurol. 19, 15-21 (1986).
12. Mork SJ, Halvorsen TB, Lindegaard KF. Eide GE. Oligodendroglioma. Histologic evaluation and prognosis. J. Neurol. Exp. Neurol. 45, 65-78 (1986).
13. Kleihues P, Cavence WK. Pathology and genetics. In: Tumors of the Nervous System Kleihues P, Cavenee W (Eds), International Agency for Research on Cancer, Lyon, France, (1997).
14. Daumas-Duport C, Tucker ML, Kolles H et al. Oligodendrogliomas. Part II. A new grading system based on morphological and imaging criteria. J. Neurooncol. 34, 61-68 (1997).
15. Kleihues P, Burger PC, Scheithauer BW. Histological Typing of Tumours of the Central Nervous System. Springer, Berlin Heidelberg New York, NY, USA, 1-105 (1993).
16. Bello MJ, Leone PE, Vaquero J et al. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int. J. Cancer 64(3), 207-210 (1995).
17. Bigner SH, Matthews MR, Rasheed BK et al. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am. J. Pathol. 155(2), 375-386 (1999).
18. Kraus JA, Koopmann J, Kaskel P et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol. Exp. Neurol. 54(1), 91-95 (1995).
19. Maintz D, Fiedler K, Koopmann J et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J. Neuropathol. Exp. Neurol. 56(10), 1098-1104 (1997).
20. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial rumors shows preferential allelic deletions on 19q and 1p. Am. J. Pathol. 145(5), 1175-1190 (1994).
21. Smith JS, Alderete B, Minn Y et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18(28), 4144-4152 (1999).
22. Nigro JM, Takahashi MA. Ginzinger DG et al. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsarellite analysis, a real-time quantitative polymerase chain reaction assay. Am J. Pathol. 158(4), 1253-1262 (2001).
23. Smith JS, Perry A. Borell TJ et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas and mixed oligoastrocytomas. J Clin. Oncol. 18(3), 636-645 (2000).
24. Wu JK, Folkerth RD, Ye Z, Darras BT. Aggressive oligodendroglioma predicted by chromosome 10 restriction fragment length polymorphism analysis. J Neurooncol. 15(1), 29-35 (1993).
25. Kros JM, van Run PF, Alers JC et al. Genetic aberrations in oligodendroglial tumours: an analysis using comparative genomic hybridization (CGH). J. Pathol. 188(3), 282-288 (1999).
26. Zhu JJ, Santarius T, Wu X et al. Screening for loss of heterozygosity and microsatellite instability in oligodendrogliomas. Genes Chromosomes Cancer 21(3), 207-216 (1998).
27. Cairncross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl Cancer Inst. 90(19), 1473-1479 (1998).
28. Jeuken JW, Sprenger SH, Wesseling P et al. Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization. J. Neuropathol. Exp. Neurol. 58(6), 606-612 (1999).
29. Rosso SM, van Dekken H, Krishnadath KK, Alers JC, Kros JM. Detection of chromosomal changes by interphase cytogenetics in biopsies of recurrent astrocytomas and oligodendrogliomas. J. Neuropathol. Exp. Neurol. 56(10), 1125-1131 (1997).
30. Pruchon E, Chauveinc L, Sabatier L et al. A cytogenetic study of 19 recurrent gliomas. Cancer Genet. Cytogenet. 76(2), 85-92 (1994).
31. Broholm H, Bols B, Heegaard S, Braendstrup O. Immunohistochemical investigation of p53 and EGFR expression of oligodendrogliomas. Clin. Neuropathol. 18(4), 176-180 (1999).
32. Reifenberger J, Reifenberger G, Ichimura K, Schmidt EE, Wechsler W, Collins VP. Epidermal growth factor receptor expression in oligodendroglial tumors. Am J. Pathol. 149(1), 29-35 (1996).
33. Reis-Filho JS, Facto LN, Carrilho C, Bleggi-Torres LF, Schmitt FC. Evaluation of cell proliferation, epidermal growth factor receptor and bcl-2 immunoexpression as prognostic factors for patients with World Health Organization Grade 2 oligodendroglioma. Cancer 88(4), 862-869 (2000).
34. Wang Y, Hagel C, Hamel W, Muller S, Kluwe L, Westphal M. Trk A, B and C are commonly expressed in human astrocytes and astrocytic gliomas but not by human oligodendrocytes and oligodendroglioma. Acta Neuropathol. (Berl). 96 (4), 357-364 (1998).
35. Zhou XP, Li YJ, Hoang-Xuan K et al. Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int, J. Cancer 84(2), 150-154 (1999).
36. Ino, Y, Betensky RA, Zlatescu MC et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin. Cancer Res. 7(4), 839-845 (2001).
37. Bello MJ, Vaquero J, de Campos JM et al. Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors. Int, J. Cancer 57(2), 172-175 (1994).
38. Guan KL, Jenkins CW, Li Y et al. Growth suppression by p18, a p16INK4/MTS1-and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild type pRb function. Genes Dev. 8(24), 2939-2952 (1994).
39. He J, Hoang-Xuan K Marie Y et al. p18 tumor suppressor gene and progression of oligodendrogliomas to anaplasia. Neurology 55(6), 867-869 (2000).
40. Barker FG, Chang SM, Huhn SL et al. Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 80, 936-941 (1997).
41. Ginsberg LE, Fuller GN, Hashmi M, Leeds NE, Schomer DF. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg. Neurol. 49, 436-440 (1998).
42. Dehghani F, Schachenmayr W, Laun A. Korf HW. Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathol. 95(5), 493-504 (1998).
43. Heegaard S, Sommer HM, Broholm. H, Broendstrup O. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer 76(10), 1809-1013 (1995).
44. Kros JM, Hop VC, Godschalk JJ, Krishnadath KK. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer 78(5), 1107-1113 (1996).
45. Coons SW, Johnson PC, Pearl DK. The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. Neurosurgery 41(4), 878-884 (1997).
46. Miettinen H, Kononen J, Sallinen P et al. CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas. J Neurooncol, 41(3), 205-211 (1999).
47. Di Rocco F, Carroll RS, Zhang J, Black PM. Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. Neurosurgery 42(2), 341-346 (1998).
48. Deininger MH, Weller M, Streffer J, Meyermann R. Anti-apoptotic Bcl-2 family protein expression increases with progression of oligodendroglioma. Cancer 86(9), 1832-1839 (1999).
49. Dehghani F, Maronde E, Schachenmayr W, Korf HW. Neurofilament H inummoreaction in oligodendrogliomas as demonstrated by a new polydonal antibody. Acta Neuropathol. 100(2), 122-130 (2000).
50. Korshunov A, Golanav A. The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases. J. Neurooncol, 48(1), 13-19 (2000).
51. Fleury A, Menegoz F, Grosclaude P et al. Descriptive epidemiology of cerebral gliomas in France. Cancer 79, 1195-1202 (1997).
52. Allam A, Radwi A, El Weshi A, Hassounah M. Oligodendroglioma: an analysis of prognostic factors and treatment results. Am. J. Clin. Oncol. 23(2), 170-175 (2000).
53. Marek J, Jakubaszko-Turkiewicz J, Oficjalska-Mlynczak J, Markowska-Woyciechowska A. Retinal oligodendroglioma. Am J Ophthalmol. 128(3), 389-391 (1999).
54. Derlon JM, Chapon F, Noel M et al. Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur. J. Nucl. Med 27(7), 778-787 (2000).
55. Holzer T. The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using f-18-fluorodeoxyglucose and c-11-L-methylmethionine. Neurosurgery 42(5), 1200-1201 (1998).
56. Herholz K, Holzer T, Bauer B et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 50(5), 1316-1322 (1998).
57. Bader JB, Samnick S, Moringlane JR. et al. Evaluation of 1-3- [123I] iodo-amethyltyrosine SPET and [18F] fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy. Eur. J. Nucl. Med. 26(2), 144-151 (1999).
58. Shaw EG, Scheithauer BW, Mallon JR, Tazelaar HD, Davis DH. Oligodendrogliomas: the Mayo clinic experience. J Neurosurg. 76, 428-434 (1992).
59. Whitton AC, Bloom HJG. Low-grade glioma of the cerebral hemispheres in adults: a retrospective analysis of 88 cases. J. Int. J. Radiat. Oncol. Biol. Phys. 18, 783-786 (1990).
60. Apuzzo MLJ. Evolving dimensions at the frontiers of human cerebral surgery. In: Benign Cerebral Glioma. Neurosurgical Topics. Apuzzo MLJ (Ed.). Am. Ass. Neurol. Surg. 1-12 (1995).
61. Ganslandt O, Steinmeier R, Kober H. et al. Magnetic source imaging combined with image-guided frameless stereotaxy: a new method in surgery around the motor strip. Neurosurgery 41(3), 621-628 (1997).
62. Cairncross G, Macdonald D, Ludwin S et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 12(10), 2013-2021 (1994).
63. Soffietti I, Borgogne M, Bradac GB, Schiffier D. Role of chemotherapy in oligodendroglial tumors: a review of the experience at the University of Torino. J. Neurooncol. 30, 153 (1996).
64. Mason WP, Krol GS, DeAngelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology 46, 203-207 (1996).
65. Duffau H, Albuquerque L, Ameri A, Sanson M, Poisson M, Delattre J-Y. Chemotherapy for newly diagnosed and recurrent anaplastic oligodendrogliomas and mixed gliomas: an analysis of 42 cases. Neurology 45(Suppl. 4), A261 (1995).
66. Streffer J, Schabet M, Bamberg M et al. A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. J. Neurol. 247(4), 297-302 (2000).
67. Wang Y, Hagel C, Hamel W, Kluwe L, Westphal M. Trk family members: potential lineage markers for glia. J. Neurooncol. 35, S47 (1997)
68. Luider Th, van den Bent MJ, Smitt PS, Vecht ChJ, Kros JM. Inventory of proteins in astrocytoma and oligodendroglioma by two-dimensional electrophoresis. J. Neurooncol. 35, S28 (1997).
69. 6-methyluanine. Cancer Res. 56, 5615-5619 (1996).
70. 6-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethytnitrosourea chemotherapy. Int. J. Cancer 69, 420-425 (1996).
71. Cairncross G, Swinnen L, Bayer R et al. Myelo-ablative chemotherapy for recurrent aggressive oligodendroglioma. Neurooncol. 2(2), 114-119 (2000).
72. Peterson K, Paleologos N, Forsyth P et al. Salvage chemotherapy for oligodendroglioma. J. Neurosurg. 85, 597-601 (1996).
73. Soffietti I. Ruda R, Bradac GB et al. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 43, 1066-1073 (1998).
74. Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU and vincristine chemotherapy: Dutch Neurooncology Group. Neurology 51, 1140-1145 (1998).
75. Levin VA, Leibel SA, Gutin PH. Neoplasms of the central nervous system. In: Cancer: Principles and Practice of Oncology De Vita VT Jr, Hellman S, Rosenberg SA (Eds), Philadelphia PA., USA, 2022-2082 (1997).
76. Paleologos NA, Macdonald DR, Vick NA et al. Neoadjuvant procarbazine, CCNU and vincristine for anaplastic and aggressive oligodendroglioma. Neurology 53, 1141-1143 (1999).
77. Hondre S, Chinot O, Dufour H, Bouillaut P, Braguer D, Grisoli F. Temodal (temozolomide) in Nitrosoureas pre-treated malignant glioma patients. Single institute study. J. Neurooncol. 39(Suppl.), 151 (1998).
78. Chinot OL, Honore S, Dufour H et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J. Clin. Oncol. 19(9), 2449-2455 (2001).
79. Newlands ES, Blackledge GR, Slack JA et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br. J. Cancer 65, 287-291 (1992).
80. O'Reilly SM, Newlands ES, Glaser MG et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur. J. Cancer 29A, 940-942 (1993).
81. Newlands ES, O'Reilly SM, Glaser MG et al. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur. J. Cancer 32A, 2236-2241 (1996).
82. Reid JM, Stevens DC, Rubin J et al. Pharmacokinetics of 3-methyl-(triazen-lyl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clin. Cancer Res. 3, 2393-2398 (1997).
83. Cairncross JG, Macdonald DR, Ramsay DA. Aggressive oligodendroglioma: a chemosensitive tumor. Neurosurgery 31, 78-82 (1991).
84. Peterson K, Paleologos N, Forsyth P, Macdonald DR, Cairncoss JG. Salvage chemotherapy for oligodendroglioma. J Neurosurg. 85, 597-601 (1996).
85. Fulton D, Urtasun R, Forsyth P. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J. Neuruoncol. 27, 149-155 (1996).
86. Chamberlain MC, Kormanik PA. Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. J. Clin. Oncol. 15, 3427-3432 (1997).
87. Fine HA, Figg WD, Jaeckle K et al. Phase II trial of the anti-angiogenic agent thalidomide in patients with recurrent high-grade gliomas. J. Clin. Oncol. 18(4), 708-715 (2000).
88. Cohen MH. Thalidomide in the treatment of high-grade gliomas. J. Clin. Oncol. 18(19), 3453 (2000).
89. Fine HA, Maher EA, Wen Y, Batchelor T, Viscosi E, Figg W. Phase II trial of thalidomide and BCNU in recurrent high-grade gliomas. Proc. 37th Ann. Soc. Clin. Oncol. San Francisco, California, CA, USA, (2001) (Abstract 218).
90. Lindegaard KF, Mork SJ, Eide GE et al. Statistical analysis of clinicopathological features, radiotherapy and survival in 170 cases of oligodendroglioma. J. Neurosurg. 67(2), 224-230 (1987).
91. Karim ABMF, Cornu P Bleehen N et al. Immediate postoperative radiotherapy in low grade glioma improve progression free survival but not overall survival: preliminary results of an EORTC/MRC randomized Phase III study. Proc. 34th Ann. Soc. Clin. Oncol. (1998) (Abstract 1544).
92. Henderson KH, Shaw EG. Randomized trials of radiation therapy in adult lowgrade gliomas. Semin. Radiat. Oncol. 11(2), 145-151 (2001).
93. Karim AB, Maat B, Hatlevoll R et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int. J. Radiat. Oncol. Biol. Phys. 36, 549-556 (1996.).
94. Shaw E, Arusell R. Scheithauer B. et al. Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Co-operative Oncology Group study. J. Clin. Oncol. 20(9), 2267-2276 (2002).